Search results for "Chronic kidney disease"
MKSAP Quiz: Follow-up for diabetes, hyperlipidemia, hypertension
A 68-year-old man is evaluated during a routine follow-up visit. Medical history is significant for type 2 diabetes mellitus, hyperlipidemia, hypertension, and aortofemoral bypass surgery 2 years ago. Following a physical exam, what is the most appropriate additional treatment?
https://immattersacp.org/weekly/archives/2022/11/15/3.htm
15 Nov 2022
Equation for kidney failure risk that excludes race shows better sensitivity, specificity than eGFR alone
The four-variable equation includes age, sex, estimated glomerular filtration rate (eGFR), and urinary albumin-creatinine ratio.
https://immattersacp.org/weekly/archives/2022/01/11/4.htm
11 Jan 2022
Guideline recommends allopurinol as first-line therapy for gout
The American College of Rheumatology noted that the drug is the preferred choice for urate-lowering therapy in all patients, including those with moderate to severe chronic kidney disease.
https://immattersacp.org/weekly/archives/2020/05/19/4.htm
19 May 2020
New trials provide data to improve medication management in hypertension
A U.K. study compared morning versus evening dosing of antihypertensive drugs, a U.S. study looked at optimal dosing in patients with proteinuria, and a trial in Spain tested self-titration in patients with poorly controlled hypertension.
https://immattersacp.org/weekly/archives/2022/10/18/6.htm
18 Oct 2022
Cardiovascular events similar, adverse effects worse with chlorthalidone compared to hydrochlorothiazide
Chlorthalidone was associated with a significantly higher risk of hypokalemia, hyponatremia, acute renal failure, chronic kidney disease, type 2 diabetes, and abnormal weight gain.
https://immattersacp.org/weekly/archives/2020/02/25/2.htm
25 Feb 2020
Meta-analysis compares mortality benefits of heart failure treatment combinations
Patients taking an angiotensin receptor-neprilysin inhibitor, beta-blocker, mineralocorticoid receptor antagonist, and sodium-glucose cotransporter-2 inhibitor showed the greatest reduction in risk of death, the analysis of heart failure with reduced ejection fraction found.
https://immattersacp.org/weekly/archives/2021/12/14/4.htm
14 Dec 2021
GLP-1 receptor agonists may offer kidney protection in patients with type 2 diabetes
An industry-conducted pooled analysis of two large trials of glucagon-like peptide-1 (GLP-1) receptor agonists found that both semaglutide and liraglutide slowed kidney function decline, with semaglutide appearing to have the greatest effect.
https://immattersacp.org/weekly/archives/2021/12/21/2.htm
21 Dec 2021
Apixaban associated with lower risk of GI bleeding compared to other DOACs
Apixaban users experienced similar rates of ischemic stroke or systemic embolism, intracranial hemorrhage, and all-cause mortality as patients taking other direct oral anticoagulants (DOACs), a retrospective analysis found.
https://immattersacp.org/weekly/archives/2022/11/01/1.htm
1 Nov 2022
Higher baclofen dosage associated with encephalopathy in older patients with CKD
A retrospective Canadian study compared 30-day risk for encephalopathy in older patients with chronic kidney disease (CKD) who were newly prescribed at least 20 mg of baclofen per day versus a lower dose, as well as in baclofen users versus nonusers.
https://immattersacp.org/weekly/archives/2019/11/12/4.htm
12 Nov 2019
Racial, economic disparities found in use of SGLT-2 inhibitors
Although use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors rose overall between 2015 and 2019, patients who were Black, Asian, female, or with lower household income had lower rates of prescriptions for the drug class than others with type 2 diabetes.
https://immattersacp.org/weekly/archives/2021/04/20/2.htm
20 Apr 2021